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Abstract
Background: There have been concerns regarding the safety of renin-angiotensin-aldosterone-system (RAAS)-
blocking agents including angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB)
during the coronavirus disease 2019 (COVID-19) pandemic. This study sought to evaluate the impact of
hypertension and the use of ACEI/ARB on clinical severity in patients with COVID-19.
Methods: A total of 3,788 patients aged 30 years or older who were confirmed with COVID-19 with real time
reverse transcription polymerase chain reaction were identified from a claims-based cohort in Korea. The primary
study outcome was severe clinical events, a composite of intensive care unit admission, need for ventilator care,
and death.
Results: Patients with hypertension (n = 1,190, 31.4 %) were older and had higher prevalence of comorbidities than
those without hypertension. The risk of the primary study outcome was significantly higher in the hypertension
group, even after multivariable adjustment (adjusted odds ratio [aOR], 1.67; 95 % confidence interval [CI], 1.04 to
2.69). Among 1,044 patients with hypertensive medical treatment, 782 (74.9 %) were on ACEI or ARB. The ACEI/ARB
subgroup had a lower risk of severe clinical outcomes compared to the no ACEI/ARB group, but this did not
remain significant after multivariable adjustment (aOR, 0.68; 95 % CI, 0.41 to 1.15).
Conclusions: Patients with hypertension had worse COVID-19 outcomes than those without hypertension, while
the use of RAAS-blocking agents was not associated with increased risk of any adverse study outcomes. The use of
ACE inhibitors or ARBs did not increase the risk of adverse COVID-19 outcomes, supporting current guidance to
continue these medications when indicated.
Keywords: Coronavirus infections, Hypertension, Angiotensin-converting enzyme inhibitors, Angiotensin receptor
antagonists
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Background
The coronavirus disease 2019 (COVID-19) is a global pan-
demic causing millions of deaths worldwide as of March
2021 [1, 2]. The pathogen of the disease, severe acute re-
spiratory syndrome coronavirus-2, uses a densely glycosyl-
ated spike (S) protein to gain entry into host cells [3].
Studies have suggested that the host receptor angiotensin-
converting enzyme 2 (ACE2) is the target of the S protein
receptor-binding domain, and that the interaction regu-
lates the transmission of the disease [4, 5].
Amid the COVID-19 pandemic, concerns have been
raised that the use of renin-angiotensin-aldosterone-sys-
tem (RAAS)-blocking agents, such as ACE inhibitors
(ACEI) and angiotensin receptor blockers (ARB) may in-
crease the susceptibility to or aggravate the severity of
COVID-19. There have been studies suggesting blockade
of either angiotensin II synthesis or activity increases the
gene expression and activity of ACE2 [6, 7]. Observations
that patients with hypertension are associated with worse
clinical outcomes triggered the concerns that the use of
ACEI or ARB may be linked with their poor prognosis.
Major cardiology societies pointed out that such spec-
ulations lack sound clinical evidence, and strongly rec-
ommended that physicians and patients should continue
treatment with their usual antihypertensive therapy [8,
9]. Hypertension is one of the most common diseases,
and strong evidence supports the benefit of medical
treatment for hypertension [10–12]. ACEI and ARB are
among the most widely used antihypertensive medica-
tions. In contrary to the initial concerns, multiple studies
have proven their safety in terms of COVID-19 suscepti-
bility and severity [13, 14]. This study aimed at estimat-
ing the impact of hypertension and the use of ACEI/
ARB on severe clinical outcomes among Korean patients
confirmed with COVID-19.
Methods
Data source and patients
South Korea is one of the countries severely affected by
COVID-19: more than 20,000 patients have been diag-
nosed and approximately 380 died as of September
2020. In response to scientific needs, the government of
Korea allowed access to de-identified COVID-19 nation-
wide patient data based on the Korean National Health
Insurance System [15]. The insurance system covers
more than 97 % of residents in Korea. The cohort com-
prised 5,483 patients confirmed by real time reverse
transcription polymerase chain reaction (RT-PCR) until
April 4, 2020. Hospitalized patients as well as those
treated at outpatient clinics were included. The database
consisted of claims information during the COVID-19
illness and the previous 5 years. Adults aged 30 years or
older (n = 3,788) were chosen in this study because
hypertension is rare in younger populations [16]. This
study was exempt from review by the Seoul National
University Bundang Hospital Institutional Review Board
(IRB No: X-2005-611-902). It complied with the require-
ments of the 2013 Declaration of Helsinki, and the need
for informed consent was waived.
Definitions
A subject was considered to have hypertension if (a)
hypertension was diagnosed once or more during a
hospitalization, or at two or more outpatient clinic visits;
or (b) a history of antihypertensive medication prescrip-
tion for more than 1 month during the prior 1 year.
Subjects with antihypertensive medical treatment were
classified into an ACEI/ARB or non-ACEI/ARB group
according to the prescription in the year prior: ACEI/
ARB use was necessary regardless of combined use of
other antihypertension medications to suffice the ACEI/
ARB group, while non-ACEI/ARB group definition in-
cluded any antihypertension drugs other than ACEI or
ARB. Previous medical history, such as ischemic heart
disease, stroke, congestive heart failure, chronic ob-
structive pulmonary disease, and cancer, was identified
based on International Classification of Diseases-10
codes from the previous 5-year claim data [17]. The pri-
mary study outcome was a composite of intensive care
unit (ICU) admission, need for ventilator care, and
death. Secondary outcomes included hospitalization,
oxygen requirement, ICU admission, need for ventilator
care, and death related to COVID-19.
Statistical analysis
Summary statistics are reported as means ± standard
deviations for numerical variables and as numbers (per-
centages) for categorical variables. Continuous variables
were compared using the Student t-test or the Mann-
Whitney U-test, as appropriate. Categorical variables
were compared using the chi-squared test. Logistic
regression models were used to calculate odds ratios
(ORs) and 95 % confidence intervals (CIs). Multivariable
regression models were constructed with adjustment for
(a) age (continuous) and sex, and (b) including age, sex,
diabetes mellitus, chronic kidney disease, chronic ob-
structive pulmonary disease, and cardiovascular disease.
A two-sided P < 0.05 was considered statistically signifi-
cant. Statistical analyses were performed using SAS ver.
9.2 (SAS Institute, Cary, NC, USA).
Results
Hypertension and COVID-19 outcomes
Among 3,788 adults aged 30 years or older who were di-
agnosed with COVID-19, 1,190 (31.4 %) had hyperten-
sion (Fig. 1). As shown in Table 1, the two groups
showed significantly different age distributions. While
the number peaked at 30 to 39 years and decreased
Kang et al. Clinical Hypertension           (2021) 27:11 Page 2 of 7
Fig. 1 Study flow diagram. ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers








Age (yr) 52.1 ± 15.1 63.9 ± 14.0 46.7 ± 12.3 < 0.001
Age distribution (yr) < 0.001
30 39 970 (25.6) 57 (4.8) 913 (35.1)
40 49 860 (22.7) 142 (11.9) 718 (27.6)
50 59 808 (21.3) 259 (21.8) 549 (21.1)
60 69 570 (15.0) 289 (24.3) 281 (10.8)
70 79 374 (9.9) 271 (22.8) 103 (4.0)
80–89 180 (4.8) 151 (12.7) 29 (1.1)
≥ 90 26 (0.7) 21 (1.8) 5 (0.2)
Male sex 1,692 (44.7) 605 (50.8) 1,087 (41.8) < 0.001
Comorbidity
Diabetes 655 (17.3) 483 (40.6) 172 (6.6) < 0.001
Dyslipidemia 1,103 (29.1) 716 (60.2) 387 (14.9) < 0.001
Chronic kidney disease 234 (6.2) 213 (18.0) 21 (0.8) < 0.001
Chronic obstructive pulmonary disease 387 (10.2) 213 (18.0) 174 (6.7) < 0.001
Cancer 313 (8.3) 153 (12.9) 160 (6.2) < 0.001
Cardiovascular disease 513 (13.5) 429 (36.1) 84 (3.2) < 0.001
Ischemic heart disease 269 (7.1) 226 (19.0) 43 (1.7) < 0.001
Myocardial infarction 36 (1.0) 34 (2.9) 2 (0.1) < 0.001
Stroke 185 (4.9) 163 (13.7) 22 (0.8) < 0.001
Congestive heart failure 223 (5.9) 191 (16.1) 32 (1.2) < 0.001
Data are presented as mean ± standard deviation or number (%)
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linearly with an increasing age in the non-hypertension
group, the hypertension group showed a broader peak
between 50 and 79 years. The proportions of male sex,
diabetes, chronic kidney disease, chronic obstructive pul-
monary disease, cardiovascular disease, and cancer were
also higher in the hypertension group.
The hypertension group showed significantly poor
outcomes compared to the non-hypertension group
(Table 2; Fig. 2). ORs for the primary study outcome, a
composite of ICU admission, ventilator care, and death,
were 5.18 (95 % CI, 3.51 to 7.65) before adjustment and
1.67 (1.04 to 2.69) after multivariable adjustment. While
hospitalization and oxygen requirement also occurred
more frequently, they were not significant after
adjustment.
RAAS-blocking agents and COVID-19 outcomes
Regarding antihypertensive medical treatment, 782 out
of 1,044 hypertensive adults (74.9 %) were prescribed
ACEI or ARB (Fig. 1). The ACEI/ARB group showed a
younger age and higher frequencies of diabetes, dyslipi-
daemia, and chronic kidney disease, while the proportion
of cancer was significantly lower than the non-ACEI/
ARB group (Table 3; Fig. 2). Meanwhile, the two groups
showed disparate patterns in antihypertensive medical
treatment.
Table 4 shows unadjusted and multivariable-adjusted
risk estimates for the study outcomes. The primary end-
point occurred in a lower rate in the ACEI/ARB group
before adjustment, which lost significance after adjust-
ment (OR, 0.68; 95 % CI, 0.41 to 1.15). While ICU ad-
mission and ventilator care tended to be lower in the
ACEI/ARB group with marginal significance, no other
study endpoints differed significantly.
Discussion
The present study showed patients with hypertension
more frequently experienced adverse outcomes than
those without hypertension when they have COVID-19
illness. The excess was greater with severe events such
as ICU admission, ventilator care, and death, whereas it
was less prominent with less severe events such as
hospitalization and oxygen requirement. Another import-
ant finding of this study is that the use of RAAS-blocking
agents such as ACEI and ARB was not associated with in-
creased risk of poor clinical prognosis associated with
COVID-19 illness.
The present study showed that use of RAAS-blocking
agents does not adversely affect clinical outcomes during
COVID-19 illness. Several recent studies consistently
showed reassuring results regarding the safety of ACEI/
ARB during the pandemic. Two studies from China also
analyzed hospitalized patients and found no excess in
mortality associated with the use of ACEI/ARB [18, 19].
Several studies even suggested lower risk of mortality as-
sociated with ACEI/ARB use [19, 20].
The current evidence of ACE2 upregulation after
chronic exposure to ACEI and ARB is mostly focused on
cardiovascular tissue [6, 7]. There is still no evidence
that they increase lung-specific ACE2 expression [13]. In
addition, experimental animal models have shown mixed
findings suggesting the complexity underlying RAAS re-
sponses to pathway modulators [13]. The present study
provides clinical evidence supporting that patients who
are taking ACEI or ARB should not discontinue their
current treatment during the COVID-19 pandemic.
Previous studies have shown that hypertension is the
most frequent comorbidity among patients with
COVID-19 and that it is also frequent in those with ad-
verse clinical outcomes [2, 21]. This study also showed
hypertension poses a risk factor for poor prognosis in
patients with COVID-19. They were also significantly
older and had higher prevalence of comorbidities. Al-
though adjustment for such factors partially attenuated
the risks, they remained significantly greater.
This study similarly showed hypertension was the
most frequent comorbidity in this study population.
However, the proportion (31.4 %) was numerically simi-
lar to the prevalence in the general Korean population
(30.5 % in adults aged 30 years or older) [16, 22].










Unadjusted Age, sex-adjusted Multivariable adjusted
OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value
Hospitalization 1,481 (39.1) 587 (49.3) 894 (34.4) 1.86 (1.61 2.13) < 0.001 0.96 (0.81 1.14) 0.634 1.15 (0.95 1.38) 0.146
Oxygen
requirement
267 (7.0) 154 (12.9) 113 (4.3) 3.27 (2.54 4.21) < 0.001 1.24 (0.92 1.68) 0.159 1.33 (0.96 1.83) 0.083
Severe outcome 123 (3.2) 85 (7.1) 38 (1.5) 5.18 (3.51 7.65) < 0.001 1.66 (1.06 2.59) 0.026 1.67 (1.04 2.69) 0.034
ICU admission 55 (1.5) 38 (3.2) 17 (0.7) 5.01 (2.82 8.91) < 0.001 2.59 (1.33 5.05) 0.005 2.69 (1.33 5.43) 0.006
Ventilator care 34 (0.9) 25 (2.1) 9 (0.3) 6.17 (2.87 13.3) < 0.001 2.50 (1.05 5.94) 0.038 2.85 (1.18 6.92) 0.020
Death 83 (2.2) 61 (5.1) 22 (0.8) 6.32 (3.87 10.3) < 0.001 1.36 (0.78 2.36) 0.274 1.24 (0.69 2.25) 0.473
Data are presented as number (%) unless otherwise specified
ICU intensive care unit, OR odds ratios, CI confidence intervals
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Regarding to the role of RAAS-blocking agents, Mancia
et al. [14] recently performed a well-designed case-
control study to demonstrate that ACEI or ARB did not
affect the risk of COVID-19. Subsequent studies also
confirmed the safety of ACEI and ARB in terms of likeli-
hood of COVID-19 infection [23, 24].
One of the strengths of the present study is the broad
spectrum of study population including outpatients as
well as in-hospital patients. Vigorous contact-tracing
and extensive testing were performed in Korea [25]. The
low rate of mortality (2.2 %) in this study compared to
other studies with RAAS-blocking agents (5.8 %, 8.8 %,
and 11.0 %) partly reflects the situation [18, 19]. We be-
lieve it ensures low risk of selection bias in this study.
However, this study also has limitations. Firstly, because
the cohort consisted of a claims database, study variables
were defined using operational definitions. However, the
use of claims data also ensures the data integrity of
Fig. 2 Risk of adverse clinical outcomes associated with hypertension and the use of RAAS-blocking agents. RAAS, renin-angiotensin-aldosterone-
system; ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers








Age (yr) 63.8 ± 14.1 63.0 ± 14.2 66.2 ± 13.6 0.002
Male sex 525 (50.3) 401 (51.3) 124 (47.3) 0.268
Comorbidity
Diabetes 410 (39.3) 333 (42.6) 77 (29.4) 0.002
Dyslipidemia 620 (59.4) 481 (61.5) 139 (53.1) 0.016
Chronic kidney disease 177 (17.0) 144 (18.4) 33 (12.6) 0.030
Chronic obstructive pulmonary disease 181 (17.3) 134 (17.1) 47 (17.9) 0.766
Cancer 119 (11.4) 80 (10.2) 39 (14.9) 0.040
Cardiovascular disease 358 (34.3) 261 (33.4) 97 (37.0) 0.282
Ischemic heart disease 185 (17.7) 137 (17.5) 48 (18.3) 0.769
Myocardial infarction 27 (2.6) 23 (2.9) 4 (1.5) 0.212
Stroke 137 (13.1) 97 (12.4) 40 (15.3) 0.235
Congestive heart failure 163 (15.6) 113 (14.5) 50 (19.1) 0.074
Antihypertensive treatment
ACEI 51 (4.9) 51 (6.5) 0 < 0.001
ARB 744 (71.3) 744 (95.1) 0 < 0.001
β-blockers 183 (17.5) 122 (15.6) 61 (23.3) 0.005
Calcium channel blockers 593 (56.8) 422 (54.0) 171 (65.3) 0.001
Diuretics 223 (21.4) 187 (23.9) 36 (13.7) 0.001
Others 100 (9.6) 48 (6.1) 52 (19.8) < 0.001
Data are presented as mean ± standard deviation or number (%)
ACEI angiotensin-converting enzyme inhibitors, ARB angiotensin receptor blockers
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COVID-19-related adverse outcomes and history of anti-
hypertensive medication usage. Second, while informa-
tion on ethnicity was absent, it is likely that most of the
patients were ethnic Korean. The narrow ethnic repre-
sentativeness is another limitation. Third, ARB outnum-
bered ACEI in the study cohort reflecting the practice
pattern in East Asia. High prevalence of adverse events
such as dry cough has been reported with the use of
ACEI in the region [26]. Lastly, claims data usually have
lag time until registration. It is possible that recent infor-
mation on medical usage may be incomplete yet.
Conclusions
This study showed hypertension is associated with poor
clinical outcomes in patients with COVID-19. However,
the use of RAAS-blocking agents, including ACEI and
ARB, was not associated with increased risk of any ad-
verse study outcomes. The present study supports the
current guidance to continue ACEI or ARB during the
COVID-19 pandemic.
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